These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36372245)

  • 61. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice.
    Aboumsallem JP; Muthuramu I; Mishra M; Kempen H; De Geest B
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871282
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems.
    Niimi N; Yako H; Takaku S; Chung SK; Sango K
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494154
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Type 2 diabetes is an independent predictor of lowered peak aerobic capacity in heart failure patients with non-reduced or reduced left ventricular ejection fraction.
    Abe T; Yokota T; Fukushima A; Kakutani N; Katayama T; Shirakawa R; Maekawa S; Nambu H; Obata Y; Yamanashi K; Nakano I; Takada S; Yokota I; Okita K; Kinugawa S; Anzai T
    Cardiovasc Diabetol; 2020 Sep; 19(1):142. PubMed ID: 32950064
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aldose reductase inhibitors: 2013-present.
    Quattrini L; La Motta C
    Expert Opin Ther Pat; 2019 Mar; 29(3):199-213. PubMed ID: 30760060
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of exercise training on outcomes in women with heart failure: analysis of HF-ACTION (Heart Failure-A Controlled Trial Investigating Outcomes of Exercise TraiNing) by sex.
    Piña IL; Bittner V; Clare RM; Swank A; Kao A; Safford R; Nigam A; Barnard D; Walsh MN; Ellis SJ; Keteyian SJ;
    JACC Heart Fail; 2014 Apr; 2(2):180-6. PubMed ID: 24720927
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    Borlaug BA; Anstrom KJ; Lewis GD; Shah SJ; Levine JA; Koepp GA; Givertz MM; Felker GM; LeWinter MM; Mann DL; Margulies KB; Smith AL; Tang WHW; Whellan DJ; Chen HH; Davila-Roman VG; McNulty S; Desvigne-Nickens P; Hernandez AF; Braunwald E; Redfield MM;
    JAMA; 2018 Nov; 320(17):1764-1773. PubMed ID: 30398602
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
    Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
    Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.
    Sharma A; Vaduganathan M; Ferreira JP; Liu Y; Bakris GL; Cannon CP; White WB; Zannad F
    J Am Heart Assoc; 2020 Jan; 9(1):e012797. PubMed ID: 31902327
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heart Failure and Diabetes: Perspective of a Dangerous Association.
    Favaloro LE; Ratto RD; Musso C
    Curr Hypertens Rev; 2021; 17(2):85-93. PubMed ID: 33823781
    [TBL] [Abstract][Full Text] [Related]  

  • 76. V̇o
    Van Iterson EH; Johnson BD; Joyner MJ; Curry TB; Olson TP
    Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H114-H124. PubMed ID: 28476919
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of streptozotocin-induced diabetes and aldose reductase inhibition with sorbinil, on left and right atrial function in the rat.
    Sellers DJ; Chess-Williams R
    J Pharm Pharmacol; 2000 Jun; 52(6):687-94. PubMed ID: 10875546
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial.
    Banks AZ; Mentz RJ; Stebbins A; Mikus CR; Schulte PJ; Fleg JL; Cooper LS; Leifer ES; Badenhop DT; Keteyian SJ; Piña IL; Kitzman DW; Fiuzat M; Whellan DJ; Kraus WE; O'Connor CM
    J Card Fail; 2016 Jul; 22(7):485-91. PubMed ID: 26687984
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aldose reductase, oxidative stress and diabetic cardiovascular complications.
    Vedantham S; Ananthakrishnan R; Schmidt AM; Ramasamy R
    Cardiovasc Hematol Agents Med Chem; 2012 Sep; 10(3):234-40. PubMed ID: 22632267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.